Overview

Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and tolerability of multiple doses of TAK-442once daily, (QD) or twice daily (BID), in subjects with acute coronary syndrome (unstable angina, myocardial infarction).

Phase:

Phase 2

Details

Lead Sponsor:

Takeda

Treatments:

1-(1-(3-((6-chloronaphthalen-2-yl)sulfonyl)-2-hydroxypropanoyl)piperidin-4-yl)tetrahydropyrimidin-2(1H)-one